Drug
TH 302 clinical trials
Also written TH-302 and Evofosfamide.
- studies test it
- 23
- open now
- 2
- in phase 3
- 1
- first study started
- 2007
Keep track of what changes. Save the TH 302 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 4 |
| 2017 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 12
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 8
Threshold Pharmaceuticals (7) · ImmunoGenesis (6) · The University of Texas Health Science Center at San Antonio (2) · Merck KGaA, Darmstadt, Germany (2) · Grupo Espanol de Tumores Neuroendocrinos (1) · Alliance for Clinical Trials in Oncology (1) · Seoul National University Hospital (1) · Herbert Hurwitz, MD (1)
Often tested with
Tested in the same studies.
Sunitinib (1) · Bevacizumab (1) · Sorafenib (1) · Pazopanib (1) · Zalifrelimab (1) · Balstilimab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1)
Studies
Open first, then newest update. How each study uses TH 302 is read from its arms, and is right about nine times in ten.
Testing it · 23
- Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate CancerNot yet recruitingPhase 2University Health Network, TorontoNCT06836726Written as Evofosfamide
- A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabRecruitingPhase 1/2ImmunoGenesisNCT06782555Written as Evofosfamide
- Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue SarcomaCompletedPhase 1/2ImmunoGenesisNCT00742963Written as TH-302
- Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic AdenocarcinomaCompletedPhase 2ImmunoGenesisNCT01144455Written as TH-302
- Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedPhase 3ImmunoGenesisNCT01746979Written as TH-302
- A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced MelanomaTerminatedPhase 2ImmunoGenesisNCT01864538Written as TH-302
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic CancerTerminatedPhase 1ImmunoGenesisNCT02047500Written as TH-302
- A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedPhase 2Grupo Espanol de Tumores NeuroendocrinosNCT02402062Written as TH-302 + Sunitinib
- TH-302 in Combination With Bevacizumab for GlioblastomaCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT02342379Written as TH-302
- Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By SurgeryCompletedPhase 1Alliance for Clinical Trials in OncologyNCT01497444Written as hypoxia-activated prodrug TH-302
- Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following BevacizumabCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT01403610Written as TH-302 preoperative
- A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaTerminatedPhase 2Merck KGaA, Darmstadt, GermanyNCT02255110Written as TH-302
- Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract CancerCompletedPhase 2Seoul National University HospitalNCT02433639Written as TH-302 monotherapy
- Immunotherapy Study of Evofosfamide in Combination With IpilimumabStatus unknownPhase 1Threshold PharmaceuticalsNCT03098160Written as Evofosfamide
- Dose Escalation Study of Pazopanib Plus TH-302CompletedPhase 1Herbert Hurwitz, MDNCT01485042Written as Pazopanib and TH-302
- A Phase 1 TH-302 Mass Balance TrialCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT02076230Written as [14C] TH-302 (Label 1)
- A Cardiac Safety Study of TH-302 in Patients With Advanced Solid TumorsStatus unknownPhase 1Threshold PharmaceuticalsNCT02020226Written as TH-302
- Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStatus unknownPhase 1/2Threshold PharmaceuticalsNCT01522872Written as TH-302
- Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.WithdrawnPhase 1Maastricht Radiation OncologyNCT02598687Written as TH-302
- Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid TumorsCompletedPhase 1/2Threshold PharmaceuticalsNCT00743379Written as TH-302
See all 23 studies that test TH 302 →